Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aspire Biopharma Holdings, Inc.

Get SEC filing alerts via email and in your feed for Aspire Biopharma Holdings, Inc.

ASBP ASBPW

Aspire Biopharma Holdings, Inc.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma is an early-stage biopharmaceutical company developing innovative sublingual drug delivery technologies. Its focus includes creating fast-acting formulations for known drugs like aspirin, with potential applications in pain management, stroke, and heart attack prevention. The company aims to commercialize products through licensing, collaborations, and direct sales, leveraging proprietary formulations, patents, and strategic partnerships in the pharmaceutical and nutraceutical markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aspire Biopharma Holdings, Inc.

1
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Reports Revenue Growth and Reduced Net Loss in Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Reports $24.48 Million Net Loss and Strategic Developments for 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Reports First Revenue of $1,941 in Q3 2025 Amid Significant Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Holdings Reports $1.98 Million Net Loss and Significant Asset Growth in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Holdings Reports $15.9 Million Net Loss and Financial Challenges in Latest 10-Q

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aspire Biopharma Holdings, Inc. Aspire Biopharma Reports $12.5 Million Net Loss and Operational Challenges in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aspire Biopharma Holdings, Inc. PowerUp Acquisition Corp. Reports Significant Financial Decline, Net Loss, and Doubt Over Going Concern in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments